Advertisement

Neurotherapeutics

, Volume 11, Issue 1, pp 68–77 | Cite as

Treatment of the Sleep Disorders Associated with Parkinson’s Disease

  • Lynn Marie TrottiEmail author
  • Donald L. Bliwise
Review

Abstract

Sleep disorders are common in patients with Parkinson’s disease (PD), and preliminary work has suggested viable treatment options for many of these disorders. For rapid eye movement sleep behavior disorder, melatonin and clonazepam are most commonly used, while rivastigmine might be a useful option in patients whose behaviors are refractory to the former. Optimal treatments for insomnia in PD have yet to be determined, but preliminary evidence suggests that cognitive–behavioral therapy, light therapy, eszopiclone, donepezil, and melatonin might be beneficial. Use of the wake-promoting agent modafinil results in significant improvement in subjective measures of excessive daytime sleepiness, but not of fatigue. Optimal treatment of restless legs syndrome and obstructive sleep apnea in PD are not yet established, although a trial of continuous positive airway pressure for sleep apnea was recently completed in PD patients. In those patients with early morning motor dysfunction and disrupted sleep, the rotigotine patch provides significant benefit.

Keywords

REM sleep behavior disorder Insomnia Excessive daytime sleepiness Fatigue Restless legs syndrome Obstructive sleep apnea 

Notes

Conflict of Interest

Dr. Trotti has served as a consultant for UCB Pharma. Dr. Bliwise has served or is serving as a consultant for Ferring Pharmaceuticals, Vantia Therapeutics, and the New England Research Institute. Full conflict of interest disclosures are available in the electronic supplementary material for this article.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Supplementary material

13311_2013_236_MOESM1_ESM.pdf (1.2 mb)
ESM 1 (PDF 1225 kb)

References

  1. 1.
    Yoritaka A, Ohizumi H, Tanaka S, Hattori N. Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol 2009;61:164-170.PubMedGoogle Scholar
  2. 2.
    De Cock V, Vidailhet M, Leu S, et al. Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 2007;2007:450-456.Google Scholar
  3. 3.
    Gagnon JF, Bedard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-589.PubMedGoogle Scholar
  4. 4.
    Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. J Neurol Neurosurg Psychiatry 2008;79:387-391.PubMedGoogle Scholar
  5. 5.
    Bliwise DL, Trotti LM, Rye DB. Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. In: Watts RL, Standaert DG, Obeso J (eds). Movement disorders. 3rd ed. McGraw-Hill, 2011, pp. 935-974.Google Scholar
  6. 6.
    Lees A, Blackburn N, Campbell V. The nightime problems of Parkinson's disease. Clin Neuropharmacol 1988;11:512-519.PubMedGoogle Scholar
  7. 7.
    Nausieda P, Glantz R, Weber S, Baum R, Klawans H. Psychiatric complications of levodopa therapy of Parkinson' disease. In: Hassler R, Christ J (eds) Advances in neurology. Raven Press, New York, 1984, pp. 271-277.Google Scholar
  8. 8.
    Factor S, McAlarney T, Sanchez-Ramos J, Weiner W. Sleep disorders and sleep effect in Parkinson's Disease. Mov Disord 1990;5:280-285.PubMedGoogle Scholar
  9. 9.
    van Hilten J, Weggeman M, Velde Evd, Kerkhof G, Dijk Jv, Roos R. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm [P-D Sect] 1993;5:235-244.Google Scholar
  10. 10.
    Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:431-435.PubMedGoogle Scholar
  11. 11.
    Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G. Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 2008;23:1420-1427.PubMedGoogle Scholar
  12. 12.
    Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl. 3):S42-80.PubMedGoogle Scholar
  13. 13.
    Hogl B, Arnulf I, Comella C, et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010;25:2704-2716.PubMedGoogle Scholar
  14. 14.
    Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 2008;23:1665-1672.PubMedGoogle Scholar
  15. 15.
    Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. J Neurol Neurosurg Psychiatry 2008;79:1117-1121.PubMedGoogle Scholar
  16. 16.
    Kumru H, Santamaria J, Tolosa E, Iranzo A. Relation between subtype of Parkinson's disease and REM sleep behavior disorder. Sleep Med 2007;8:779-783.PubMedGoogle Scholar
  17. 17.
    Trotti LM. REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management. Drugs Aging 2010;27:457-470.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Iranzo A, Santamaria J, Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med Rev 2009;13:385-401.PubMedGoogle Scholar
  19. 19.
    Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46:388-393.PubMedGoogle Scholar
  20. 20.
    Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572-577.PubMedGoogle Scholar
  21. 21.
    Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-1300.PubMedGoogle Scholar
  22. 22.
    Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med 2011;7:639-644A.PubMedGoogle Scholar
  23. 23.
    Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.PubMedGoogle Scholar
  24. 24.
    Wing YK, Lam SP, Li SX, et al. REM sleep behaviour disorder in Hong Kong Chinese: clinical outcome and gender comparison. J Neurol Neurosurg Psychiatry 2008;79:1415-1416.PubMedGoogle Scholar
  25. 25.
    Schenck CH, Hurwitz TD, Mahowald MW. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res 1993;2:224-231.PubMedGoogle Scholar
  26. 26.
    Sforza E, Krieger J, Petiau C. REM sleep behavior disorder: clinical and physiopathological findings. Sleep Med Rev 1997;1:57-69.PubMedGoogle Scholar
  27. 27.
    Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996;100:333-337.PubMedGoogle Scholar
  28. 28.
    Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009;5:235-239.PubMedGoogle Scholar
  29. 29.
    Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010;6:85.PubMedGoogle Scholar
  30. 30.
    Takeuchi N, Uchimura N, Hashizume Y, et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001;55:267-269.PubMedGoogle Scholar
  31. 31.
    Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999;14:507-511.PubMedGoogle Scholar
  32. 32.
    Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-284.PubMedGoogle Scholar
  33. 33.
    Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 2010;19:591-596.PubMedGoogle Scholar
  34. 34.
    McCarter SJ, Boswell CL, St Louis EK, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med 2013;14:237-242.PubMedGoogle Scholar
  35. 35.
    Kotagal V, Albin RL, Muller ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012;71:560-568.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord 2012;27:559-561.PubMedGoogle Scholar
  37. 37.
    Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000;55:870-871.PubMedGoogle Scholar
  38. 38.
    Massironi G, Galluzzi S, Frisoni GB. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr 2003;15:377-383.PubMedGoogle Scholar
  39. 39.
    Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2010;25:1030-1038.PubMedGoogle Scholar
  40. 40.
    Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology 2003;61:1418-1420.PubMedGoogle Scholar
  41. 41.
    Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med 2006;7:418-423.PubMedGoogle Scholar
  42. 42.
    Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med 2012;226:177-181.PubMedGoogle Scholar
  43. 43.
    Kumru H, Iranzo A, Carrasco E, et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep 2008;31:1418-1421.PubMedGoogle Scholar
  44. 44.
    Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 2013;19:153-157.PubMedGoogle Scholar
  45. 45.
    Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord 1996;11:214-216.PubMedGoogle Scholar
  46. 46.
    Yamauchi K, Takehisa M, Tsuno M, et al. Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease. Gen Hosp Psychiatry 2003;25:140-142.PubMedGoogle Scholar
  47. 47.
    Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978;43:143-151.PubMedGoogle Scholar
  48. 48.
    Sixel-Doring F, Trautmann E, Mollenhauer B, Trenkwalder C. Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease? Sleep Med 2012;13:1178-1183.PubMedGoogle Scholar
  49. 49.
    Bliwise DL, Trotti LM, Greer SA, Juncos JJ, Rye DB. Phasic muscle activity in sleep and clinical features of Parkinson disease. Ann Neurol 2010;68:353-359.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol 2009;32:158-159.PubMedGoogle Scholar
  51. 51.
    Bamford CR. Carbamazepine in REM sleep behavior disorder. Sleep 1993;16:33-34.PubMedGoogle Scholar
  52. 52.
    Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986;9:293-308.PubMedGoogle Scholar
  53. 53.
    Nash JR, Wilson SJ, Potokar JP, Nutt DJ. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 2003;61:1161.PubMedGoogle Scholar
  54. 54.
    Vaughan CP, Juncos JL, Trotti LM, Johnson TM, 2nd, Bliwise DL. Nocturia and overnight polysomnography in Parkinson disease. Neurourol Urodynam 2013 Jan 28.Google Scholar
  55. 55.
    Dobkin RD, Menza M, Bienfait KL, et al. Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management. Am J Geriatr Psychiatry 2011;19:222-229.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report. Sleep 2006;29:1415-1419.PubMedGoogle Scholar
  57. 57.
    Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - A randomized study. Parkinsonism Relat Disord 2013;19:670-675.PubMedGoogle Scholar
  58. 58.
    Menza M, Dobkin RD, Marin H, et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord 2010;25:1708-1714.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Daniele A, Albanese A, Gainotti G, Gregori B, Bartolomeo P. Zolpidem in Parkinson's disease. Lancet 1997;349:1222-1223.PubMedGoogle Scholar
  60. 60.
    Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor, and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res 2011;20:552-558.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Werneck ALS, Rosso AL, Vincent MB. The use of an antagonist 5-HT2A/C for depression and motor function in Parkinson's disease. Arq Neuropsiquiatr 2009;67:407-412.PubMedGoogle Scholar
  62. 62.
    Oderda LH, Young JR, Asche CV, Pepper GA. Psychotropic-related hip fractures: Meta-analysis of first generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother 2012;46:917-928.PubMedGoogle Scholar
  63. 63.
    Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Ip EJ, Bui QV, Barnett MJ, et al. The effect of trazodone on standardized field sobriety tests. Pharmacotherapy 2013;33:369-374.PubMedGoogle Scholar
  65. 65.
    Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhaes MC, de Lourdes Seabra M, de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007;254:459-464.PubMedGoogle Scholar
  66. 66.
    Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005;20:1151-1158.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50.PubMedGoogle Scholar
  68. 68.
    Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 2005;28:185-187.PubMedGoogle Scholar
  69. 69.
    Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-1649.PubMedGoogle Scholar
  70. 70.
    Borbely AA. A two process model of sleep regulation. Hum Neurobiol 1982;1:195-204.PubMedGoogle Scholar
  71. 71.
    Rye DB, Bliwise DL, Dihenia B, Gurecki P. FAST TRACK: daytime sleepiness in Parkinson's disease. J Sleep Res 2000;9:63-69.PubMedGoogle Scholar
  72. 72.
    Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004;61:97-102.PubMedGoogle Scholar
  73. 73.
    Roth T, Rye DB, Borchert LD, et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med 2003;4:275-280.PubMedGoogle Scholar
  74. 74.
    Bliwise DL, Trotti LM, Wilson AG, et al. Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class. Mov Disord 2012;27:1118-1124.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Wienecke M, Werth E, Poryazova R, et al. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? J Sleep Res 2012;21:710-717.PubMedGoogle Scholar
  76. 76.
    Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-1794.PubMedGoogle Scholar
  77. 77.
    Lou JS, Dimitrova DM, Park BS, et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2009;32:305-310.PubMedGoogle Scholar
  78. 78.
    Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293.PubMedGoogle Scholar
  79. 79.
    Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639.PubMedGoogle Scholar
  80. 80.
    Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25:905-909.PubMedGoogle Scholar
  81. 81.
    Tyne HL, Taylor J, Baker GA, Steiger MJ. Modafinil for Parkinson's disease fatigue. J Neurol 2010;257:452-456.PubMedGoogle Scholar
  82. 82.
    Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-931.PubMedGoogle Scholar
  83. 83.
    Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-658.PubMedGoogle Scholar
  84. 84.
    Meter V, Jr. Therapy of Parkinson's disease. Calif Med 1950;73:322-324.PubMedCentralGoogle Scholar
  85. 85.
    Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22:2070-2076.PubMedGoogle Scholar
  86. 86.
    Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011;17:156-159.PubMedGoogle Scholar
  87. 87.
    Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 2008;65:1337-1340.PubMedGoogle Scholar
  88. 88.
    Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep 2012;35:1039-1062.PubMedGoogle Scholar
  89. 89.
    Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012;19:1385-1396.PubMedGoogle Scholar
  90. 90.
    Kedia S, Moro E, Tagliati M, Lang AE, Kumar R. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 2004;63:2410-2412.PubMedGoogle Scholar
  91. 91.
    Chahine LM, Ahmed A, Sun Z. Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleep-related measures. Parkinsonism Relat Disord 2011;17:208-211.PubMedGoogle Scholar
  92. 92.
    Driver-Dunckley E, Evidente VG, Adler CH, et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord 2006;21:1287-1289.PubMedGoogle Scholar
  93. 93.
    Trotti LM, Bliwise DL. No increased risk of obstructive sleep apnea in Parkinson's disease. Mov Disord 2010;25:2246-2249.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Cochen De Cock V, Abouda M, Leu S, et al. Is obstructive sleep apnea a problem in Parkinson's disease? Sleep Med 2010;11:247-252.PubMedGoogle Scholar
  95. 95.
    Diederich NJ, Vaillant M, Leischen M, et al. Sleep apnea syndrome in Parkinson's disease. A case-control study in 49 patients. Mov Disord 2005;20:1413-1418.PubMedGoogle Scholar
  96. 96.
    Yong MH, Fook-Chong S, Pavanni R, Lim LL, Tan EK. Case control polysomnographic studies of sleep disorders in Parkinson's disease. PLoS One 2011;6:e22511.PubMedCentralPubMedGoogle Scholar
  97. 97.
    Norlinah MI, Afidah KN, Noradina AT, et al. Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS. Parkinsonism Relat Disord 2009;15:670-674.PubMedGoogle Scholar
  98. 98.
    Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002;162:893-900.PubMedGoogle Scholar
  99. 99.
    Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006:CD001106.Google Scholar
  100. 100.
  101. 101.
    Phillips CL, Grunstein RR, Darendeliler MA, et al. Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2013;187:879-887.PubMedGoogle Scholar
  102. 102.
    Ferreira JJ, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology 2002;58:460-462.PubMedGoogle Scholar
  103. 103.
    Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008:CD006564.Google Scholar
  104. 104.
    Nausieda P. Sleep in Parkinson disease. In: Thorpy N (ed.) Handbook of sleep disorders. Marcel Dekker, New York, 1990, pp. 719-733.Google Scholar
  105. 105.
    Leeman AL, O'Neill CJ, Nicholson PW, et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987;24:637-643.PubMedGoogle Scholar
  106. 106.
    Wolters EC, Horstink MW, Roos RA, Jansen EN. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. Clin Neurol Neurosurg 1992;94:205-211.PubMedGoogle Scholar
  107. 107.
    Wolters EC, Tesselaar HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J Neurol 1996;243:235-240.PubMedGoogle Scholar
  108. 108.
    Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J. Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. Eur J Neurol 2011;18:590-596.PubMedGoogle Scholar
  109. 109.
    Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115.PubMedGoogle Scholar
  110. 110.
    Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol 2012;19:105-113.PubMedGoogle Scholar
  111. 111.
    Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-99.PubMedCentralPubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2013

Authors and Affiliations

  1. 1.Department of NeurologyEmory University School of MedicineAtlantaUSA

Personalised recommendations